ZYME (Zymeworks) Cyclically Adjusted Book per Share: $6.74 (As of Mar. 2026)


ZYME Zymeworks Inc ZYME
66 GF Score
Price $26.31
GF Value $24.08
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Zymeworks Cyclically Adjusted Book per Share?

Zymeworks ZYME +2.47% 66 Cyclically Adjusted Book per Share is $6.74 as of Mar. 2026. GuruFocus rates ZYME with a GF Score™ of 66/100 and a GF Value™ of $24.08 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Zymeworks's adjusted book value per share for the three months ended in Mar. 2026 was $2.221. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $6.74 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-03), Zymeworks's current stock price is $26.31. Zymeworks's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $6.74. Zymeworks's Cyclically Adjusted PB Ratio of today is 3.90.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Zymeworks was 4.17. The lowest was 2.46. And the median was 3.55.


Zymeworks  (NAS:ZYME) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Zymeworks's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=26.31/6.74
=3.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Zymeworks was 4.17. The lowest was 2.46. And the median was 3.55.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Zymeworks Cyclically Adjusted Book per Share Related Terms


Zymeworks Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Zymeworks's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zymeworks Cyclically Adjusted Book per Share Chart

Zymeworks Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 6.74

Zymeworks Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 6.69 6.74 6.74

ZYME vs SRPT, BCAX, INVA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Zymeworks's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zymeworks Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zymeworks's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Zymeworks's Cyclically Adjusted PB Ratio falls into.


ZYME
66GF Score
Zymeworks Inc ZYME
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zymeworks Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zymeworks's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.221/330.2130*330.2130
=2.221

Current CPI (Mar. 2026) = 330.2130.

Zymeworks Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.457 241.432 0.625
201703 -0.456 243.801 -0.618
201706 3.826 244.955 5.158
201709 3.259 246.819 4.360
201712 4.576 246.524 6.129
201803 3.712 249.554 4.912
201806 5.836 251.989 7.648
201809 5.308 252.439 6.943
201812 5.644 251.233 7.418
201903 5.305 254.202 6.891
201906 8.526 256.143 10.992
201909 7.869 256.759 10.120
201912 6.210 256.974 7.980
202003 11.473 258.115 14.678
202006 10.782 257.797 13.811
202009 9.440 260.280 11.976
202012 8.905 260.474 11.289
202103 8.170 264.877 10.185
202106 6.953 271.696 8.451
202109 5.992 274.310 7.213
202112 5.341 278.802 6.326
202203 4.889 287.504 5.615
202206 3.848 296.311 4.288
202209 2.914 296.808 3.242
202212 7.817 296.797 8.697
202303 7.389 301.836 8.084
202306 6.632 305.109 7.178
202309 6.247 307.789 6.702
202312 6.629 306.746 7.136
202403 6.197 312.332 6.552
202406 5.734 314.175 6.027
202409 5.274 315.301 5.523
202412 4.912 315.605 5.139
202503 4.670 319.799 4.822
202506 4.435 322.561 4.540
202509 4.228 324.800 4.298
202512 3.571 324.054 3.639
202603 2.221 330.213 2.221

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $6.74 mean?
Zymeworks (ZYME) has a Cyclically Adjusted Book per Share of $6.74 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Zymeworks and its competitors.
Is Zymeworks' Cyclically Adjusted Book per Share too high?
Zymeworks' current Cyclically Adjusted Book per Share is $6.74. Overall, Zymeworks has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zymeworks' Cyclically Adjusted Book per Share compare to SRPT and BCAX?
Zymeworks' Cyclically Adjusted Book per Share of $6.74 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Zymeworks and its competitors. Zymeworks's current Cyclically Adjusted Book per Share is $6.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zymeworks stock overvalued right now?
Based on GuruFocus' analysis, Zymeworks (ZYME) is currently considered Fairly Valued. The stock's GF Value™ is $24.08, compared to a current price of $26.31 — trading 9.3% above its estimated fair value. The current Cyclically Adjusted Book per Share is $6.74. Zymeworks' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Zymeworks (ZYME), the current Cyclically Adjusted Book per Share is $6.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zymeworks (ZYME) Overvalued in 2026?

Based on GuruFocus' analysis, Zymeworks stock appears to be overvalued. The current stock price of $26.31 is trading 9.3% above its estimated GF Value™ of $24.08. GuruFocus considers Zymeworks to be Fairly Valued.

Key valuation signals for ZYME:

  • Cyclically Adjusted Book per Share: $6.74
  • GF Value™: $24.08 vs. price of $26.31 (9.3% above fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the ZYME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zymeworks Business Description

Other Exchanges ZA8:Germany
Address 108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
66GF Score

Get the complete analysis for ZYME

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.31
Price
$24.08
GF Value